Pilot trial of verucerfont (NBI-77860) in adult females with classic congenital adrenal hyperplasia

Trial Profile

Pilot trial of verucerfont (NBI-77860) in adult females with classic congenital adrenal hyperplasia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2015

At a glance

  • Drugs Verucerfont (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Biomarker; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 09 Feb 2015 According to a Neurocrine Biosciences media release, a full description of the study results and related data will be presented at the Endocrine Society's 97th Annual Meeting 2015.
    • 22 Jan 2015 New trial record
    • 10 Dec 2014 According to a Neurocrine Biosciences media release, an orphan drug status for verucerfont (NBI-77860) in classic congenital adrenal hyperplasia from the FDA has been requested.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top